Independent medical research charity MRC Technology has teamed up with Peptinnovate to assess potential therapies in bone diseases.
Peptinnovate, which is developing first-in-class disease modifying medicines for immuno-inflammatory diseases, will investigate its unique peptides derived from the bacterium mycobacterium tuberculosis, the pathogen that causes TB.
Natural peptides from the pathogen are able to modify the immunological and inflammatory response in humans. Peptinnovate is investigating whether the properties could form the basis of new medicines for a variety of disease indications that involve altered immune responses.
Andrew Lightfoot, CEO, Peptinnovate, said: “We are delighted to be working with experts at MRC Technology to better understand the potential of our approach in the treatment of bone diseases, our second area of therapeutic focus.
“Peptinnovate is continuing to develop strongly, following on from our recent Biomedical Catalyst funding success, which stands us in good stead for future fundraising and partnering.”
The collaboration is a result of interaction by Stevenage Bioscience Catalyst, where Peptinnovate is based and MRC Technology is relocating next year.
Martino Picardo, CEO at Stevenage Bioscience Catalyst, added: “This partnership is just the kind of interaction Stevenage Bioscience Catalyst was established to facilitate and drive.
“It’s great to see this collaboration between one of our first and one of our newest tenants, and we hope to see many more fruitful relationships as the campus continues its rapid development.”